Skip to main content
EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · EYPT ISIN · US74440J1016 LEI · 549300QE1RU34T50MR69 US Manufacturing
Open in API
Filings indexed 1,019 across all filing types
Latest filing 2016-02-16 Major Shareholding Noti…
Country US United States of America
Listing US EYPT

About EyePoint Pharmaceuticals, Inc.

https://eyepointpharma.com/

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Recent filings

Filing Released Lang Actions
ORBIS INVESTMENT MANAGEMENT LIMITED
Major Shareholding Notification
2016-02-16 English
SC 13G/A
Major Shareholding Notification
2016-02-12 English
FORM 10-Q
Interim / Quarterly Report Q2 2016
2016-02-09 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated February 5, 2016. The key content is the resignation of a board member, Peter G. Savas, from the company's board of directors, including details about his service and committee memberships. This fits the description of announcements related to changes in the company's board of directors or senior management. The document is not a full annual or quarterly report, nor is it an earnings release or other financial report. It is specifically about management changes, which aligns with the Board/Management Information category (MANG). The document length is short and focused solely on this event, confirming it is not a broader report or announcement type.
2016-02-08 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 8, 2016, reporting the company's second quarter fiscal year 2016 results via a press release (Exhibit 99.1). The text explicitly states that the press release announces the results but does not contain the full financial statements or detailed financial analysis itself. The document length is 2659 characters, which is relatively short and mainly serves as an announcement of the earnings release rather than the earnings release itself. According to the rules, initial announcements of quarterly financial results (key highlights only) are classified as Earnings Release (ER). Since this is a Form 8-K announcing the earnings results and including a press release, it fits the Earnings Release category rather than a full Interim/Quarterly Report (IR) or Annual Report (10-K).
2016-02-08 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 7, 2016, reporting the entry into an underwriting agreement for a public offering of common stock. It details the terms of the offering, including the number of shares, price, and option for additional shares. The document includes exhibits such as the underwriting agreement, legal opinion, and press releases announcing the offering and its pricing. The content focuses on a financing event related to the company's capital structure. The document length is 4175 characters, which is relatively short but contains substantive information about the financing transaction itself, not just an announcement of a report. Therefore, it is classified as a Capital/Financing Update (CAP).
2016-01-08 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.